Sophiris
Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a
biopharmaceutical company developing PRX302 for the treatment of the
symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and
for the treatment of localized low to intermediate risk prostate cancer,
today announced that Randall E. Woods, president and chief executive
officer, will present a corporate overview at the 26th Annual
Piper Jaffray Healthcare Conference. The presentation is scheduled for
Tuesday, December 2, 2014 at 12:50 p.m. EST in New York City.
The presentation will be webcast live and can be accessed through the
Investor Relations page at www.sophiris.com.
A replay of the presentation will be available on the Company’s website
for 90 days.
About Sophiris
Sophiris Bio Inc. is a biopharmaceutical company developing PRX302, a
clinical-stage, targeted therapy for the treatment of the symptoms of
BPH and treatment of low to intermediate risk localized prostate cancer.
PRX302 is in Phase 3 clinical development for the treatment of the
symptoms of BPH and is designed to be as efficacious as pharmaceuticals,
less invasive than the surgical interventions, and without the sexual
side effects seen with existing treatments. Sophiris plans to initiate a
Phase 2 proof of concept study of PRX302 for the treatment of localized
low to intermediate risk prostate cancer prior to the end of the first
quarter of 2015. For more information, please visit www.sophiris.com.
For more information, please visit www.sophiris.com.
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements, and therefore these statements should not be
read as guarantees of future performance or results. All forward-looking
statements are based on Sophiris’ current beliefs as well as assumptions
made by and information currently available to Sophiris and relate to,
among other things, anticipated financial performance, business
prospects, strategies, regulatory developments, market acceptance and
future commitments. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date of
this press release. Due to risks and uncertainties, including the risks
and uncertainties identified by Sophiris in its public securities
filings; actual events may differ materially from current expectations.
Sophiris disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Copyright Business Wire 2014